Michele T Yip-Schneider
Overview
Explore the profile of Michele T Yip-Schneider including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
949
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Qadir M, Baril J, Yip-Schneider M, Schonlau D, Tran T, Schmidt C, et al.
medRxiv
. 2025 Jan;
PMID: 39830259
Background: Based on the Fukuoka and Kyoto international consensus guidelines, the current clinical management of intraductal papillary mucinous neoplasm (IPMN) largely depends on imaging features. While these criteria are highly...
2.
Yip-Schneider M, Muraru R, Rao N, Kim R, Rempala-Kurucz J, Baril J, et al.
Cureus
. 2024 Jun;
16(5):e60240.
PMID: 38872680
Introduction: Pancreatic cancer remains one of the deadliest cancers in the United States. Some types of pancreatic cysts, which are being detected more frequently and often incidentally on imaging, have...
3.
Leon-Letelier R, Dou R, Vykoukal J, Yip-Schneider M, Maitra A, Irajizad E, et al.
Clin Chem
. 2024 Jan;
70(1):102-115.
PMID: 38175578
Background: Increasing evidence implicates microbiome involvement in the development and progression of pancreatic ductal adenocarcinoma (PDAC). Studies suggest that reflux of gut or oral microbiota can lead to colonization in...
4.
Yip-Schneider M, Muraru R, Kim R, Wu H, Sherman S, Gutta A, et al.
HPB (Oxford)
. 2023 Sep;
25(12):1587-1594.
PMID: 37749004
Background/objectives: Pancreatic serous cystic neoplasms (SCN) present a diagnostic challenge given their increasing frequency of detection and benign nature yet relatively high rate of misdiagnosis. Here, imaging and analyses associated...
5.
Masterson A, Chowdhury N, Fang Y, Yip-Schneider M, Hati S, Gupta P, et al.
ACS Sens
. 2023 Feb;
8(3):1085-1100.
PMID: 36853001
Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy that is often detected at an advanced stage. Earlier diagnosis of PDAC is key to reducing mortality. Circulating biomarkers such as microRNAs...
6.
Caiazza F, Conroy P, Ivry S, York T, Lin J, Hernandez S, et al.
J Surg Res
. 2022 Nov;
284:322-331.
PMID: 36369049
Introduction: The accurate identification of mucinous pancreatic cystic lesions (PCLs) is paramount for cancer risk stratification. Cyst fluid carcinoembryonic antigen (CEA), the only routinely used test, requires high volumes and...
7.
Yip-Schneider M, Wu H, Allison H, Easler J, Sherman S, Al-Haddad M, et al.
J Am Coll Surg
. 2021 Jun;
233(3):426-434.e4.
PMID: 34166836
Background: Pancreatic cysts are incidentally detected in up to 13% of patients undergoing radiographic imaging. Of the most frequently encountered types, mucin-producing (mucinous) pancreatic cystic lesions may develop into pancreatic...
8.
Evrimler S, Yip-Schneider M, Swensson J, Soufi M, Muraru R, Tirkes T, et al.
Abdom Radiol (NY)
. 2021 Jun;
46(10):4779-4786.
PMID: 34086091
Purpose: Assess the relationship between MRI-derived pancreatic fat fraction and risk of malignancy in intraductal papillary mucinous neoplasm (IPMN). Methods: MRIs of patients with IPMN who underwent pancreaticoduodenectomy were analyzed....
9.
Soufi M, DePeralta D, Simpson R, Flick K, Yip-Schneider M, Schmidt 2nd C, et al.
Anticancer Res
. 2021 Apr;
41(4):1895-1901.
PMID: 33813394
Background/aim: We created a novel, preoperative wellness program (WP) that promotes recovery. This study assessed its impact on patient outcomes after pancreatectomy. Patients And Methods: Pancreatoduodenectomies (PD) and distal pancreatectomies...
10.
Yip-Schneider M, Wu H, Schmidt C
Biochimie
. 2021 Jan;
181:234-239.
PMID: 33387563
Vascular endothelial growth factor (VEGF)-A is known to play key biological roles in angiogenesis and vascular permeability. We previously identified VEGF-A as an accurate biomarker of benign pancreatic cystic lesions...